Merck KGaA Company
Merck KGaA is currently assessing an interferon beta approved by the FDA for the treatment of relapsing forms of multiple sclerosis; Rebif® (interferon beta-1a).
Merck KGaA said March 19 it donated Rebif to the French Institut National de la Santé et de la Recherche Médicale (INSERM) following a request for use in a clinical trial. The trial (DisCoVeRy; 2020-000936-23 and NCT04315948) —sponsored by INSERM and launched March 11 — is comparing Rebif to AbbVie’s Kaletra, Gilead Sciences ’Remdesivir, and Sanofi’s Plaquenil (hydroxychloroquine) in 3,100 patients.
Headquarters:
Germany
Employee Number:
N/A
Founded Date:
N/A
Investment Stage:
N/A
Technology:
COVID
Investor Type:
N/A
Number Of Exists:
N/A
Industry:
Treatments
Funding Status:
N/A